title: An overview of corneal collagen cross-linking (CXL).
abstract: Corneal collagen cross-linking (CXL) was first described over a decade ago and is now considered to be one of the most important surgical innovations of modern ophthalmology. Prior to its introduction, no interventions were available to arrest, or slow down ectatic disease progression, with corneal transplantation required in the majority of cases. Unlike earlier treatments of corneal ectasias that attempted to only improve the consequences of the disease, CXL aims to address the corneal biomechanical weakening itself. The long-term safety and efficacy of CXL have been established in several studies that have documented significant improvements in all outcome measures (visual acuity, spherical equivalent, astigmatism, and keratometric findings). The emerging combination of CXL with other interventions (termed 'CXL plus') optimizes the visual and topographic outcomes. This, along with the expansion of the techniques' indications for other clinical conditions, such as microbial keratitis, highlights the continuous improvement of the initial technique and confirms its wide acceptance. Overall, CXL has already demonstrated much promise and has several clinical indications, representing a clear example of recent advances in ocular therapy.
authors.affiliation: Faculty of Medicine, Institute of Vision and Optics, University of Crete, Heraklion, Greece.
authors.forename: George D
authors.initials: GD
authors.lastname: Kymionis
authors.forename: Dimitrios G
authors.initials: DG
authors.lastname: Mikropoulos
authors.forename: Dimitra M
authors.initials: DM
authors.lastname: Portaliou
authors.forename: Irini C
authors.initials: IC
authors.lastname: Voudouragkaki
authors.forename: Vassilios P
authors.initials: VP
authors.lastname: Kozobolis
authors.forename: Anastasios G P
authors.initials: AG
authors.lastname: Konstas
mesh_terms: D003094:Collagen / Q000378:metabolism*; D003316:Corneal Diseases / Q000532:radiotherapy*; D003320:Corneal Ulcer / Q000532:radiotherapy; D015818:Eye Infections, Bacterial / Q000532:radiotherapy; D006801:Humans; D007634:Keratitis / Q000532:radiotherapy; D007640:Keratoconus / Q000532:radiotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D012256:Riboflavin / Q000627:therapeutic use*; D014467:Ultraviolet Therapy / Q000379:methods*
chemical_list: D017319:Photosensitizing Agents; D003094:Collagen; D012256:Riboflavin